Clinical Trial: NCT03959891
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Massachusetts General Hospital |
| Information Provided By: | Massachusetts General Hospital |
| Last Update Posted: | 2026-08-19 |
Study Overview
Brief Summary
This study is exploring the safety/tolerabtility and preliminary efficacy of the combination of Ipatasertib with Aromatase inhibitor or Fulvestrant for patients with metastatic HR+ breast cancer.
Official Title
Clinical Trial to Evaluate Safety and Anti-tumor Activity of AKT Inhibitor, Ipatasertib,With Endocrine Therapy With/Without CDK 4/6 Inhibitor for Patients With Metastatic Hormone Receptor Positive Breast Cancer (TAKTIC)
Conditions
Breast Cancer
Intervention / Treatment
- Drug: Ipatasertib
- Drug: Fulvestrant
- Drug: Aromatase Inhibitor
- Drug: Palbociclib
Other Study ID Numbers
- 19-086
Start Date (Actual)
2019-05-30
Primary Completion Date (Actual)
2022-12-25
Study Completion Date (Estimated)
2027-08
Enrollment (Actual)
77
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Massachusetts General Hospital |
| Information Provided By: | Massachusetts General Hospital |
| Last Update Posted: | 2026-08-19 |
Study Overview
Brief Summary
This study is exploring the safety/tolerabtility and preliminary efficacy of the combination of Ipatasertib with Aromatase inhibitor or Fulvestrant for patients with metastatic HR+ breast cancer.
Official Title
Clinical Trial to Evaluate Safety and Anti-tumor Activity of AKT Inhibitor, Ipatasertib,With Endocrine Therapy With/Without CDK 4/6 Inhibitor for Patients With Metastatic Hormone Receptor Positive Breast Cancer (TAKTIC)
Conditions
Breast Cancer
Intervention / Treatment
- Drug: Ipatasertib
- Drug: Fulvestrant
- Drug: Aromatase Inhibitor
- Drug: Palbociclib
Other Study ID Numbers
- 19-086
Start Date (Actual)
2019-05-30
Primary Completion Date (Actual)
2022-12-25
Study Completion Date (Estimated)
2027-08
Enrollment (Actual)
77
Study Type
Interventional
Phase
Phase 1